Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients

Journal of the Neurological Sciences

Volumn 213, Issue 1-2, 2003, Pages 61-65

  Müller, Thomas ^a   Meisel, Margareta ^a   Russ, Herrmann ^a   Przuntek, Horst ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Color discrimination; Color vision; Parkinson's disease; Peg insertion

Indexed keywords

ARTICLE; CLINICAL ARTICLE; COLOR DISCRIMINATION; COLOR VISION; COLOR VISION TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; TASK PERFORMANCE; VISUAL STIMULATION;

EID: 0037827344     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00150-3     Document Type: Article

References (37)

1. Bodis-Wollner I., Yahr M.D. Measurements of visual evoked potentials in Parkinson's disease. Brain. 101(4):1978;661-671.
2. Stanzione P., Fattapposta F., Tagliati M., D'Alessio C., Marciani M.G., Foti A.et al. Dopaminergic pharmacological manipulations in normal humans confirm the specificity of the visual (PERG-VEP) and cognitive (P300) electrophysiological alterations in Parkinson's disease. Electroencephalogr. Clin. Neurophysiol. 41:1990;216-220. (Suppl.).
3. Bodis-Wollner I., Tagliati M. The visual system in Parkinson's disease. Adv. Neurol. 60:1993;390-394.
4. Harris J. Vision in Parkinson's disease: what are the deficits and what are their origins? Neuro. Ophthalmol. 19:1998;113-135.
5. Harnois C., Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophthalmol. Vis. Sci. 31(11):1990;2473-2475.
6. Kinnear P.R. Proposals for scoring and assessing the 100-Hue test. Vision Res. 10(5):1970;423-433.
7. Pieri V., Diederich N.J., Raman R., Goetz C.G. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J. Neurol. Sci. 172(1):2000;7-11.
8. Büttner T., Kuhn W., Müller T., Patzold T., Heidbrink K., Przuntek H. Distorted color discrimination in 'de novo' parkinsonian patients. Neurology. 45(2):1995;386-387.
9. Müller T., Kuhn W., Buttner T., Przuntek H. Colour vision abnormalities and movement time in Parkinson's disease. Eur. J. Neurol. 6(6):1999;711-715.
10. Müller T., Kuhn W., Buttner T., Eising E., Coenen H., Haas M.et al. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease. J. Neurol. 245(10):1998;659-664.
11. Müller T., Kuhn W., Buttner T., Przuntek H. Distorted colour discrimination in Parkinson's disease is related to severity of the disease. Acta Neurol. Scand. 96(5):1997;293-296.
12. Regan B.C., Freudenthaler N., Kolle R., Mollon J.D., Paulus W. Colour discrimination thresholds in Parkinson's disease: results obtained with a rapid computer-controlled colour vision test. Vision Res. 38(21):1998;3427-3431.
13. Müller T., Benz S. Quantification of the dopaminergic response in Parkinson's disease. Parkinsonism Relat. Disord. 8(1):2002;181-186.
14. Müller T., Benz S., Przuntek H. Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. Can. J. Neurol. Sci. 29(1):2002;73-77.
15. Buddenberg L.A., Davis C. Test-retest reliability of the purdue pegboard test. Am. J. Occup. Ther. 54(5):2000;555-558.
16. Vingerhoets F.J., Schulzer M., Calne D.B., Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann. Neurol. 41(1):1997;58-64.
17. Müller T., Schafer S., Kuhn W., Przuntek H. Correlation between tapping and inserting of pegs in Parkinson's disease. Can. J. Neurol. Sci. 27(4):2000;311-315.
18. Büttner T., Kuhn W., Patzold T., Przuntek H. L-Dopa improves colour vision in Parkinson's disease. J. Neural Transm. Parkinson's Dis. Dementia Sect. 7(1):1994;13-19.
19. Büttner T., Müller T., Kuhn W. Effects of apomorphine on visual functions in Parkinson's disease. J. Neural Transm. 107(1):2000;87-94.
20. Hutton J.T., Morris J.L., Elias J.W. Levodopa improves spatial contrast sensitivity in Parkinson's disease. Arch. Neurol. 50(7):1993;721-724.
21. Nutt J.G., Lea E.S., Van Houten L., Schuff R.A., Sexton G.J. Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice. Mov. Disord. 15(5):2000;843-849.
22. Soliveri P., Brown R.G., Jahanshahi M., Marsden C.D. Effect of practice on performance of a skilled motor task in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 55(6):1992;454-460.
23. Haug B.A., Kolle R.U., Trenkwalder C., Oertel W.H., Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain. 118(Pt. 3):1995;771-778.
24. Sandberg M.A., Berson E.L. Blue and green cone mechanisms in retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 16(2):1977;149-157.
25. Hood D.C., Benimoff N.I., Greenstein V.C. The response range of the blue-cone pathways: a source of vulnerability to disease. Invest. Ophthalmol. Vis. Sci. 25(7):1984;864-867.
26. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci. 13(7):1990;296-302.
27. Dacey D.M. The dopaminergic amacrine cell. J. Comp. Neurol. 301(3):1990;461-489.
28. Ehinger B. Connections between retinal neurons with identified neurotransmitters. Vision Res. 23(11):1983;1281-1291.
29. Dubois B., Pillon B. Cognitive deficits in Parkinson's disease. J. Neurol. 244(1):1997;2-8.
30. Brown R.G., Marsden C.D. Internal versus external cues and the control of attention in Parkinson's disease. Brain. 111(Pt. 2):1988;323-345.
31. Brown R.G., Marsden C.D. Dual task performance and processing resources in normal subjects and patients with Parkinson's disease. Brain. 114(Pt. 1A):1991;215-231.
32. Claus J.J., Mohr E. Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Acta Neurol. Scand. 93(5):1996;346-351.
33. Meco G., Gasparini M., Doricchi F. Attentional functions in multiple system atrophy and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 60(4):1996;393-398.
34. Dunnewold R.J., Jacobi C.E., van Hilten J.J. Quantitative assessment of bradykinesia in patients with Parkinson's disease. J. Neurosci. Methods. 74(1):1997;107-112.
35. Lalonde R., Botez-Marquard T. The neurobiological basis of movement initiation. Rev. Neurosci. 8(1):1997;35-54.
36. Braak H., Braak E., Yilmazer D., de Vos R.A., Jansen E.N., Bohl J. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J. Neural Transm. 48:1996;1-6. (Suppl.).
37. Braak H., Braak E., Yilmazer D., Schultz C., de Vos R.A., Jansen E.N. Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. 46:1995;15-31. (Suppl.).